Industry News (RSV)

Therapeutic Monoclonal Antibody Approved for Respiratory Syncytial Virus Disease

Published in TB and Outbreaks Week, July 13th, 1998

The U.S. Food and Drug Administration (FDA) has approved a monoclonal antibody to protect high-risk infants against the worst effects of respiratory syncytial virus (RSV) disease, the most common cause of lower respiratory infections in children.

The product, palivizumab, is a genetically engineered antibody against the RSV virus. This antibody is manufactured using human and mouse antibody genes and can be produced consistently on a large scale.

Palivizumab is the second product licensed for RSV disease. The first one, RSV Immune Globulin Intravenous (Human) (RSVIGIV) is made from human plasma and is marketed as RespiGam by MedImmune Inc,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB and Outbreaks Week

Source: TB and Outbreaks Week (1998-07-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry